Your Health, We Care
Most common adverse reactions, including laboratory abnormalities (all Grades, incidence ≥ 20%) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, gamma-glutamyl transferase (GGT) increased, nausea, alanine aminotransferase (ALT) increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, activated partial thromboplastin time (aPTT) prolonged, and alopecia.
from FDA,2022.11
The purpose of this article is to provide comprehensive guidance for patients an···【more】
Release date：2024-12-20Recommended：188
Apellix is a drug that targets the PI3Kα pathway, providing a new treatment opti···【more】
Release date：2024-12-20Recommended：142
Alpelisib, an innovative targeted therapy drug, brings new hope for specific typ···【more】
Release date：2024-12-20Recommended：163
As a PIK3CA kinase inhibitor, Alpelisib plays an important role in the relations···【more】
Release date：2024-08-27Recommended：247
Alpelisib effectively treats patients with HR/HER2- breast cancer harboring PIK3···【more】
Release date：2024-08-26Recommended：273
As the first PI3Kα inhibitor, Alpelisib has shown significant efficacy in the tr···【more】
Release date：2024-08-26Recommended：281
